PepBank has 3 SYN-AKE studies with results. 2 of them gave SYN-AKE, with 8 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.
Searches 8 results and 3 papers. Newer studies from Europe PMC
Identifiers, parent molecule, targets and development stage, from curated data.
SYN-AKE is the trade name for dipeptide diaminobutyroyl benzylamide diacetate. Its structure contains beta-alanine, proline and diaminobutyric acid with a benzylamide terminus. It differs from snake venom and waglerin-1.
| Target | Action | Evidence |
|---|---|---|
| Muscle-type nicotinic acetylcholine receptor | Antagonist | Not statedSource (opens in a new tab) |
Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.
3 amino acids · 3 modifications
No sequence is listed for the parent, so no alignment is shown.The manufacturer describes a functional mimic based on the Arg-Pro-Lys motif. SYN-AKE is not a literal Waglerin-1 fragment. No parent residue range was assigned.
Some values cannot be calculated. The sequence has a non-canonical residue (X). Residue tables cover only the 20 standard amino acids.
@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses
No charge curve
The sequence has a non-canonical residue (X). Residue tables cover only the 20 standard amino acids.
3 residues. Each residue counts in one class; F and W count as aromatic.
No 3D structure
No experimental structure (PDB) and no UniProt entry for an AlphaFold model are listed for this peptide. Synthetic peptides often have neither. The sequence view above is the reference.
Draws the structure in your browser with RDKit (about 2.3 MB, loaded once).
SMILES fromPubChem CID 71465152(opens in a new tab)
CC(=O)O.CC(=O)O.C1C[C@H](N(C1)C(=O)CCN)C(=O)N[C@@H](CCN)C(=O)NCC2=CC=CC=C2People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.
PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.
Counts are exact and come from studies that gave the peptide.
Studies by year
3 of 3 studies have results (100%), published 2024 to 2026. Top row: every study. Bottom row: studies with results about SYN-AKE, by class. The rows use different scales.
Studies3 in all, 2024 to 2026
Studies with results3 in all, 2024 to 2026
Retracted studies are left out. A study with results in two classes counts in both.
AI wrote and checked these results. AI can make mistakes, so check important results against the source.
Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.
0 trials match. Highest phase first. Data from ClinicalTrials.gov.
No trial matches these filters.
Studies on this peptide. Some have results. The others have none yet.
3 studies match. Retracted studies are left out.
Showing 3 of 3 studiesquery qry_a12f4e452c724ed781c4b5ba
3 studies
In vitro (cell-free) · 2024
Gok et al. 2024Journal of biomolecular structure & dynamicscited by 9
PMID 37349941DOI 10.1080/07391102.2023.2223681PUB-37349941
Not a test of SYN-AKE alone · 2026
Zhu et al. 2026International journal of cosmetic science
PMID 41668671PMC13636123DOI 10.1111/ics.70087PUB-41668671
In vitro (cells) · 2026
Gok et al. 20263 Biotech
PMID 42927054DOI 10.1007/s13205-026-05090-6PUB-42927054
Page 1 of 1
Gok B · 3 Biotech · 2026
In vitro (cells) · 8 results
Gok B · Journal of biomolecular structure & dynamics · 2024
In vitro (cell-free) · 6 results
Zhu M · International journal of cosmetic science · 2026
Not a test of SYN-AKE alone · 17 results
Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.
| Jurisdiction | Body | Status | As of | Source |
|---|---|---|---|---|
| US | FDA | FDA assigns UNII 38H206R00R. FDA states that UNII availability does not imply regulatory review or approval. No FDA medicine approval was established. | 27 Oct 2026 | precision.fda.gov (opens in a new tab) |
| EU | EMA | No EMA medicine authorisation was established in the source search. A cosmetic ingredient listing does not establish medicinal authorisation. | 27 Oct 2026 | Not recorded |
| Sport | WADA | Status unknown Neither SYN-AKE nor its INCI name appears by name in the checked 2026 list. | 2026 List | wada-ama.org (opens in a new tab) |
| European Union | Note | INCI: DIPEPTIDE DIAMINOBUTYROYL BENZYLAMIDE DIACETATE. CosIng reference 82650. Secondary ingredient dictionaries report this entry. The official page did not return the ingredient detail during this check. An inventory entry is not a medicinal approval. | 27 Oct 2026 | specialchem.com (opens in a new tab) |
| China | Note | DSM reported CFDA listing in July 2014 for its cosmetic peptide. This company report does not establish medicinal approval or current national register status. | 27 Oct 2026 | dsm-firmenich.com (opens in a new tab) |
3 safety results for SYN-AKE.
No safety results from studies in people
In laboratory tests, the Syn‑Ake nanoemulsion formulation was non-genotoxic.
In vitro (cells)
In laboratory tests, the Syn‑Ake nanoemulsion formulation was cytocompatible.
In vitro (cells)
In laboratory safety tests, researchers determined a safe Syn‑Ake dose without reporting its value in the abstract.
Other design
The doses that these studies used. They are not recommendations.
No dose was reported in the study results.
PepBank is a research reference. Talk to a doctor before you use any peptide.
Data version, change history and code for this peptide.
curl -s https://Evidence summary for SYN-AKE: counts by class, key results with sources, notices, data version.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Top outcomes
The 4 outcome groups with the most study results, by evidence class.
Data version 308560. Bar length is the number of results, not the size of an effect.
Evidence matrix
Study results by outcome and evidence class. Arrows show how the measured outcome moved, not whether the change is good.
| Outcome group | Human | Animal | Lab | Computer model | Total |
|---|---|---|---|---|---|
| Adverse eventsSkin and wound | No results | No results | Lab: 3 results from 2 studies: 3 not reported. Strongest design: In vitro (cells) | No results | 3 |
| Oxidative stressSkin and wound | No results | No results | Lab: 2 results from 2 studies: 1 increase, 1 not reported. Strongest design: In vitro (cell-free) | No results | 2 |
| Skin and hairSkin and wound | No results | No results | Lab: 2 results from 1 study: 1 decrease, 1 not reported. Strongest design: In vitro (cells) | No results | 2 |
| Wound healingSkin and wound | No results | No results | Lab: 1 result from 1 study: 1 not reported. Strongest design: In vitro (cells) | No results | 1 |
4 outcome groups shown of 4 · 8 study results
Data version 308560. Shade grows with the number of results. Every cell shows the exact count.